Rapid Diagnosis Possible at POC
By LabMedica International staff writers Posted on 05 Mar 2013 |
Image: The hand-held cobas h 232 is suitable for use in different clinical settings, from the General Practitioner’s office to the Emergency Room (Photo courtesy of Roche).
A versatile handheld device enables rapid diagnosis at point of care (POC).
In hospitals, Roche's (Burgess, United Kingdom) products can support laboratory services by providing accurate diagnosis of patient samples and enabling rapid diagnosis of medical conditions in the emergency ward, intensive care, and in the operating theatre.
Forth Valley Royal Hospital (United Kingdom) has reduced lengths of stay and ward admissions for patients presenting with chest pain, as well as ensuring rapid referral for patients with positive findings, through the introduction of a Chest Pain Assessment Unit (CPAU). This unit provides patient care and rapid access to diagnostic testing, including Troponin T testing, using the Roche point of care (POC) cardiac marker system, cobas h 232.
“Prior to opening the CPAU, patients at low risk of Acute Coronary Syndrome (ACS) were spending a long time in hospital unnecessarily, often overnight, while ACS was ruled out,” explained nurse consultant-acute medicine, Sharon Oswald. “To obtain real-time results that enable rapid decisions to be made, we introduced the Roche cobas h 232 system for point-of-care Troponin T testing. The cobas h 232 has had a huge impact on the service. Before we introduced it, Troponin T tests were batched and performed four times per day in the laboratory. There were sometimes delays in getting the bloods to the laboratory and then in getting results back. Now, with the cobas h 232 systems, we are able to obtain results in real time, which allows faster decision making.”
“The cobas h 232 system is very sensitive,” Sharon added. “A six month comparative evaluation demonstrated that we were getting comparable results to the laboratory method. We still send positives to the laboratory for confirmation but negative results do not require further confirmation. This means [we can exclude] ACS more quickly, allowing earlier discharge. Patients that require further investigation or care can be referred immediately or given a planned return appointment.”
Related Links:
Roche
Forth Valley Royal Hospital
In hospitals, Roche's (Burgess, United Kingdom) products can support laboratory services by providing accurate diagnosis of patient samples and enabling rapid diagnosis of medical conditions in the emergency ward, intensive care, and in the operating theatre.
Forth Valley Royal Hospital (United Kingdom) has reduced lengths of stay and ward admissions for patients presenting with chest pain, as well as ensuring rapid referral for patients with positive findings, through the introduction of a Chest Pain Assessment Unit (CPAU). This unit provides patient care and rapid access to diagnostic testing, including Troponin T testing, using the Roche point of care (POC) cardiac marker system, cobas h 232.
“Prior to opening the CPAU, patients at low risk of Acute Coronary Syndrome (ACS) were spending a long time in hospital unnecessarily, often overnight, while ACS was ruled out,” explained nurse consultant-acute medicine, Sharon Oswald. “To obtain real-time results that enable rapid decisions to be made, we introduced the Roche cobas h 232 system for point-of-care Troponin T testing. The cobas h 232 has had a huge impact on the service. Before we introduced it, Troponin T tests were batched and performed four times per day in the laboratory. There were sometimes delays in getting the bloods to the laboratory and then in getting results back. Now, with the cobas h 232 systems, we are able to obtain results in real time, which allows faster decision making.”
“The cobas h 232 system is very sensitive,” Sharon added. “A six month comparative evaluation demonstrated that we were getting comparable results to the laboratory method. We still send positives to the laboratory for confirmation but negative results do not require further confirmation. This means [we can exclude] ACS more quickly, allowing earlier discharge. Patients that require further investigation or care can be referred immediately or given a planned return appointment.”
Related Links:
Roche
Forth Valley Royal Hospital
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines